research use only
Cat.No.S2728
| Related Targets | VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 c-Kit |
|---|---|
| Other EGFR Inhibitors | Lazertinib (YH25448) Icotinib Hydrochloride Sunvozertinib AG-490 Canertinib (CI-1033) WZ4002 Poziotinib (NOV120101, HM781-36B) Rociletinib (CO-1686) Genistein Allitinib tosylate |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| U87MG | Growth inhibitory assay | ~100 μM | DMSO | IC50=34.6 μM | 8752145 | |
| U87MG.ΔEGFR | Growth inhibitory assay | ~100 μM | DMSO | IC50=8.7 μM | 8752145 | |
| U87MG.wtEGFR. | Growth inhibitory assay | ~100 μM | DMSO | IC50=48.4 μM | 8752145 | |
| U87MG | Kinase assay | ~100 μM | DMSO | inhibits EGFR tyrosine kinase activity | 8752145 | |
| U87MG.ΔEGFR | Kinase assay | ~100 μM | DMSO | inhibits EGFR tyrosine kinase activity | 8752145 | |
| U87MG.wtEGFR. | Kinase assay | ~100 μM | DMSO | inhibits EGFR tyrosine kinase activity | 8752145 | |
| HPV 16-immortalized human keratinocytes | Growth inhibitory assay | ~50 μM | DMSO | inhibits cell growth | 9288782 | |
| HPV 16-immortalized human keratinocytes | Function assay | ~50 μM | DMSO | induces arrest in the Cell Cycle | 9288782 | |
| HPV 16-immortalized human keratinocytes | Apoptosis assay | ~50 μM | DMSO | induces apoptosis. | 9288782 | |
| A431 | Kinase assay | ~10 μM | DMSO | inhibits the basal and TGF-α-stimulated tyrosine phosphorylation of the EGFR | 10702262 | |
| MDA-468 | Kinase assay | ~10 μM | DMSO | inhibits the basal and TGF-α-stimulated tyrosine phosphorylation of the EGFR | 10702262 | |
| A431 | Function assay | ~10 μM | DMSO | induces cell cycle arrest | 10702262 | |
| MDA-MB-231 | Kinase assay | ~5 μM | DMSO | inhibits EGF stimulated phosphorylation of FKHR | 11030146 | |
| CNE2 | Growth inhibitory assay | 100 μM | DMSO | inhibits cell proliferation by 98.4% | 11410322 | |
| CNE2 | Kinase assay | ~100 μM | DMSO | inhibits EGFR tyrosine phosphorylation | 11410322 | |
| CNE2 | Function assay | ~100 μM | DMSO | Inhibits MAPK and AKT activation | 11410322 | |
| CNE2 | Function assay | ~50 μM | DMSO | affects cell cycle distribution | 11410322 | |
| HSC-2 | Kinase assay | 8 μM | DMSO | inhibits phosphorylation of EGFR and Akt | 17689285 | |
| HSC-2 | Apoptosis assay | 8 μM | DMSO | inhibits Fas-mediated apoptosis | 17689285 | |
| HEp-2 | Growth inhibitory assay | ~10 μM | DMSO | enhances oridonin-induced growth-inhibitory | 20202741 | |
| SubG1 | Apoptosis assay | ~10 μM | DMSO | enhances oridonin-induced apoptosis | 20202741 | |
| HEp-2 | Function assay | ~10 μM | DMSO | enhances Oridonin-induced Bax activation, Bcl-2 degradation and SIRT1 inactivation | 20202741 | |
| H508 | Growth inhibitory assay | ~1 μM | DMSO | mitigates CPF-mediated H508 cell growth | 26514924 | |
| A431 | Antiproliferative assay | Tested for antiproliferative activity against human A431 cells, IC50=20μM | 15109642 | |||
| HeLa | Function assay | 30 mins | Inhibition of EGFR autophosphorylation in human HeLa cells preincubated for 30 mins prior to EGF stimulation by Western blotting | 21718029 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| HEK293 | Function assay | 1 hr | Inhibition of human full length PKMYT1 expressed in HEK293 cells using EFS (247 to 259 residues) as substrate after 1 hr by fluorescence polarization immunoasay, Ki=1.87μM | 29941193 | ||
| HEK293 | Function assay | 1 hr | Inhibition of human full length PKMYT1 expressed in HEK293 cells using EFS (247 to 259 residues) as substrate after 1 hr by fluorescence polarization immunoasay, IC50=19.6μM | 29941193 | ||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 25 mg/mL
(79.17 mM)
Ethanol : 13 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 315.75 | Formula | C16H14ClN3O2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 153436-53-4,175178-82-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Tyrphostin AG-1478, NSC 693255 | Smiles | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC | ||
| Targets/IC50/Ki |
EGFR
(Cell-free assay) 3 nM
|
|---|---|
| In vitro |
AG-1478 is high selective over ErbB2 and PDGFR with IC50 of >100 μM. This compound preferentially inhibits U87MG cells expressing truncated EGFR with IC50 of 8.7 μM, compared to those expressing endogenous wt EGFR or overexpressing exogenous wt EGFR with IC50 of 34.6 μM and 48.4 μM, respectively, and inhibits the DNA synthesis with IC50 of 4.6 μM, 19.67 μM, and 35.2 μM, respectively. This chemical also preferentially inhibits the tyrosine kinase activity and autophosphorylation of the ΔEGFR compared to endogenous or overexpressed exogenous wt EGFR. It (0.25 μM) abolishes the MAPK activation induced by Ang II, a Ca2+ ionophore as well as EGF but not by a phorbol ester or platelet-derived growth factor-BB in the VSMC. This compound inhibits EGF-induced mitogenesis of the BaF/ERX and LIM1215 cells with IC50 of 0.07 μM and 0.2 μM, respectively. It is able to inhibit the function of ATP-binding cassette (ABC) transporters such as ABCB1 and ABCG2, with a more pronounced effect on ABCG2. |
| In vivo |
Administration of AG-1478 blocks phosphorylation of the EGFR at the tumor site and inhibits the growth of A431 xenografts that overexpress the WT EGFR and glioma xenografts expressing the de2-7 EGFR. Even subtherapeutic doses of this compound significantly enhance the efficacy of cytotoxic drugs, with the combination of this chemical displaying synergistic antitumor activity against human glioma xenografts. The combination of this compound and an anti-EGFR antibody (mAb 806) displays additive and in some cases synergistic, antitumor activity against tumor xenografts overexpressing the EGFR. The combination of this compound (0.4 mg) with a single dose of 25 μCi 90Y-CHX-A''-DTPA-hu3S193 results in a significant enhancement of efficacy compared with either agent alone. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Growth inhibition assay | Cell viability |
|
25258648 |
| Western blot | Shc / PLC-γ1 EGFR / Neu / p-Tyr |
|
10931950 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.